JPWO2020064748A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020064748A5 JPWO2020064748A5 JP2021517252A JP2021517252A JPWO2020064748A5 JP WO2020064748 A5 JPWO2020064748 A5 JP WO2020064748A5 JP 2021517252 A JP2021517252 A JP 2021517252A JP 2021517252 A JP2021517252 A JP 2021517252A JP WO2020064748 A5 JPWO2020064748 A5 JP WO2020064748A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- ketamine
- sequences
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 43
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 10
- 229960003299 ketamine Drugs 0.000 claims 10
- 239000000843 powder Substances 0.000 claims 10
- 239000012458 free base Substances 0.000 claims 8
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical group C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 6
- 229960000450 esketamine Drugs 0.000 claims 6
- 230000002685 pulmonary effect Effects 0.000 claims 5
- 230000002045 lasting effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 claims 2
- 239000004606 Fillers/Extenders Substances 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229960004184 ketamine hydrochloride Drugs 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18461615.9 | 2018-09-28 | ||
| EP18461615.9A EP3628313B1 (en) | 2018-09-28 | 2018-09-28 | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| PCT/EP2019/075735 WO2020064748A1 (en) | 2018-09-28 | 2019-09-24 | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022502429A JP2022502429A (ja) | 2022-01-11 |
| JP2022502429A5 JP2022502429A5 (https=) | 2022-09-28 |
| JPWO2020064748A5 true JPWO2020064748A5 (https=) | 2022-09-28 |
| JP7444864B2 JP7444864B2 (ja) | 2024-03-06 |
Family
ID=63713806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517252A Active JP7444864B2 (ja) | 2018-09-28 | 2019-09-24 | 肺投与によるうつ病の処置方法における使用のためのケタミン組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11925607B2 (https=) |
| EP (3) | EP3628313B1 (https=) |
| JP (1) | JP7444864B2 (https=) |
| KR (1) | KR102867739B1 (https=) |
| CN (1) | CN113038941A (https=) |
| AU (1) | AU2019349624B2 (https=) |
| BR (1) | BR112021005687A2 (https=) |
| CA (1) | CA3114325A1 (https=) |
| EA (1) | EA202190724A1 (https=) |
| ES (2) | ES3021221T3 (https=) |
| HU (2) | HUE071303T2 (https=) |
| MX (1) | MX2021003668A (https=) |
| PL (2) | PL3628313T3 (https=) |
| WO (1) | WO2020064748A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| GB0523031D0 (en) * | 2005-11-11 | 2005-12-21 | Yaupon Therapeutics | Enhancement of morphine analgesia by s(-)-norketamine |
| WO2007111880A2 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| PE20141906A1 (es) | 2012-03-12 | 2014-12-05 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento |
| WO2014020155A1 (en) | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| CN116251084A (zh) | 2013-03-15 | 2023-06-13 | 詹森药业有限公司 | S-盐酸氯胺酮的药物组合物 |
| CN106714789A (zh) * | 2014-08-13 | 2017-05-24 | 詹森药业有限公司 | 用于治疗抑郁症的方法 |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| CN106562952B (zh) * | 2015-10-09 | 2020-06-09 | 江阴安博生物医药有限公司 | 氯胺酮在治疗重性抑郁障碍中的应用 |
| PL3505157T3 (pl) * | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
-
2018
- 2018-09-28 EP EP18461615.9A patent/EP3628313B1/en active Active
- 2018-09-28 ES ES18461615T patent/ES3021221T3/es active Active
- 2018-09-28 PL PL18461615.9T patent/PL3628313T3/pl unknown
- 2018-09-28 HU HUE18461615A patent/HUE071303T2/hu unknown
-
2019
- 2019-09-24 EA EA202190724A patent/EA202190724A1/ru unknown
- 2019-09-24 PL PL19770131.1T patent/PL3856159T3/pl unknown
- 2019-09-24 US US17/281,136 patent/US11925607B2/en active Active
- 2019-09-24 BR BR112021005687-4A patent/BR112021005687A2/pt unknown
- 2019-09-24 EP EP19770131.1A patent/EP3856159B1/en active Active
- 2019-09-24 EP EP25162744.4A patent/EP4578505A3/en active Pending
- 2019-09-24 CA CA3114325A patent/CA3114325A1/en active Pending
- 2019-09-24 CN CN201980075601.XA patent/CN113038941A/zh active Pending
- 2019-09-24 ES ES19770131T patent/ES3028459T3/es active Active
- 2019-09-24 WO PCT/EP2019/075735 patent/WO2020064748A1/en not_active Ceased
- 2019-09-24 JP JP2021517252A patent/JP7444864B2/ja active Active
- 2019-09-24 MX MX2021003668A patent/MX2021003668A/es unknown
- 2019-09-24 KR KR1020217011554A patent/KR102867739B1/ko active Active
- 2019-09-24 HU HUE19770131A patent/HUE071649T2/hu unknown
- 2019-09-24 AU AU2019349624A patent/AU2019349624B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025204271A1 (en) | Microcrystalline diketopiperazine compositions and methods | |
| ES2979060T3 (es) | Combinaciones de un antagonista de receptores muscarínicos y un agonista de receptores adrenérgicos beta-2 | |
| JP2020073494A5 (https=) | ||
| RU2001123923A (ru) | Композиции, включающие формотерол и соль тиотропия | |
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2014515373A5 (https=) | ||
| JP2021510682A5 (https=) | ||
| JP2020023536A (ja) | Ｃｏｐｄの治療のためのフォルモテロール及びブデソニドの組み合わせ | |
| SE527190C2 (sv) | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid | |
| HRP20120286T1 (hr) | Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti | |
| CA2420532A1 (en) | Pharmaceutical formulation of salmeterol and fluticasone propionate | |
| CA2838031A1 (en) | Dry powder inhaler compositions comprising umeclidinium | |
| ES2371601T3 (es) | Composición para inhalación. | |
| JP2022502429A5 (https=) | ||
| JPWO2020064748A5 (https=) | ||
| KR20230005937A (ko) | 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법 | |
| EP2957552B1 (en) | Vilanterol formulations | |
| AU2003292120A1 (en) | New synergistic combination comprising roflumilast and formoterol | |
| AU2013100007A4 (en) | System for treating chronic obstructive pulmonary disease | |
| AU2020103517A4 (en) | Ibp- nebulizer: intelligent nebulizer for bronchitis patients | |
| EP2957551B1 (en) | Dry powder formulations comprising vilanterol | |
| JP2016502992A5 (https=) | ||
| EP3856159B1 (en) | Ketamine composition for use in a method of treatment of depression by pulmonary administration | |
| AU2013100008B4 (en) | Inhalable formulations of glycopyrronium bromide | |
| CN112999204A (zh) | 一种双黄连雾化吸入用溶液制剂及其制备方法 |